Angion Biomedica Corporation - news published 81 - readings 1.182

BACK
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer - Form 8-K

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer •ELI-002 2P is an investigational therapeutic cancer vaccine targeting solid tumors driven by G12D and G12R mutations in KRAS •As of the April 25, 2023 data cut-off date, among the 22 evaluable ...

Continue reading
28.09.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer

The text version of this document is not available. You can access the original document here . Attachments Original Link Original Document Permalink Disclaimer Angion Biomedica Corporation published this content on 27 September 2023 and is solely responsible for the information contained therein. Distributed by Public , unedited and unaltered, on 27 September 2023 21:35:33 UT ...

Continue reading
27.09.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines September 7, 2023 Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations ...

Continue reading
07.09.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines - Form 8-K

Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines •Funds will advance research into ELI-007, a mutant BRAF-peptide vaccine, and ELI-008, a p53 hotspot mutation-peptide vaccine, with the aim of developing multivalent cancer vaccines targeting several mutations •This $2.6 m ...

Continue reading
07.09.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 6, 2023 BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today annou ...

Continue reading
06.09.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer

Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer September 5, 2023 BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage b ...

Continue reading
05.09.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Initial Registration Statement for Employee Benefit Plan - Form S-8

As filed with the Securities and Exchange Commission on August 21, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Elicio Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3430072 (State or other jurisdiction of incorporation o ...

Continue reading
21.08.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Quarterly Report for Quarter Ending June 30, 2023 (Form 10-Q)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECU ...

Continue reading
14.08.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates - Form 8-K

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates •ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCO •AMPLIFY-7P first patient dosed with ELI-002 7P •Completed reverse merger becoming a publicly traded company on Nasdaq •Anticipate releasing additional AMPLIFY-201 clinical data in second hal ...

Continue reading
11.08.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates

Elicio Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Updates August 11, 2023 ELI-002 2P positive interim data from AMPLIFY-201 Phase 1 study presented at ASCO AMPLIFY-7P first patient dosed with ELI-002 7P Completed reverse merger becoming a publicly traded company on Nasdaq Anticipate releasing additional AMPLIFY-201 clinical data in second ...

Continue reading
11.08.2023
Angion Biomedica Corporation

Angion Biomedica Corporation

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model

Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating AMP-CpG Adjuvant Can Induce Potent and Durable Immune Response in Epstein-Barr Virus (EBV) Infectious Disease Model August 9, 2023 AMP-CpG directed vaccine to lymph nodes inducing broad humoral and cellular immunity against multiple viral determinants expressed during the EBV life cycle AMP-CpG immuniz ...

Continue reading
09.08.2023